Cell Line Development Market Scope And Analysis

Report Code : TIPHE100001196
Category : Biotechnology

No. of Pages : 150

Buy Now

Cell Line Development Market Scope and Analysis Report by 2031

Buy Now

Cell Line Development Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 6.86 Billion
Market Size by 2031	US$ 18.62 Billion
Global CAGR (2023 - 2031)	13.3%
Historical Data	2021-2022
Forecast period	2023-2031
Segments Covered	By Type Primary Cell Line Hybridomas Continuous Cell Lines Recombinant Cell Line By Product Equipment Media Reagent By Application Drug Discovery Bioproduction Tissue Engineering
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Thermo Fisher Scientific Inc Merck KGaA Selexis SA JSR Corporation BioFactura Inc Corning Incorporated Sartorius AG Lonza GENERAL ELECTRIC LakePharma Inc WuXi AppTec Group

Cell Line Development Market News and Recent Developments

The cell line development market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for cell line development and strategies:

Abzena announced on Jan. 16, 2023 the launch of AbZelect and AbZelectPRO, its new cell line development (CLD) platforms, designed to speed up the generation of production cell lines for the manufacture of antibodies and recombinant proteins. The platforms are intended to enable the rapid progress of complex biologic drug programs towards clinical trials and investigational new drug (IND) application filing. (Source: Abzena Company Name, Newletter, 2023)
Lonza announced the launch of its new GS Effex cell line for the development of therapeutic antibodies with enhanced potency. The GS Effex cell line was developed to meet pressing market needs originating from the shift towards more sophisticated therapeutic antibodies. Derived from Lonza’s leading GS Xceed cell line, GS Effex fits effectively into Lonza platforms. Combined with good cell growth and the ability to produce therapeutic antibodies with increased potency, the new cell line provides a solution for therapeutic development from discovery stage research through to commercial manufacturing. (Source: Lonza Company Name, Press Release, 2023)

Cell Line Development Market Report Coverage and Deliverables

The “Cell Line Development Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Market dynamics such as drivers, restraints, and key opportunities
Key future trends
Detailed PEST/Porter’s Five Forces and SWOT analysis
Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
Detailed company profiles